Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp (EMBC) is a global leader in diabetes care innovation, specializing in insulin delivery systems and digital health solutions for improved patient outcomes. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, product developments, and strategic initiatives.
Access comprehensive coverage of EMBC press releases, including quarterly earnings reports, regulatory milestones like FDA clearances, and partnerships advancing diabetes care technology. The page serves as a centralized resource for tracking the company’s progress in developing next-generation devices such as high-capacity patch pumps and integrated digital platforms.
Key updates include announcements on insulin delivery innovations, manufacturing expansions, and market penetration strategies. Content is organized to help users efficiently monitor Embecta’s position in the competitive medical devices sector while maintaining compliance with healthcare regulations.
Bookmark this page for direct access to verified Embecta Corp updates, ensuring you stay informed about critical developments affecting one of diabetes care’s most established medical technology providers.
Embecta Corp. (Nasdaq: EMBC) reported its Q1 fiscal year 2023 results, with revenues of $275.7 million, down 4.7% year-over-year. Adjusted net income was $55.4 million, or $0.96 per diluted share. While U.S. revenues fell 1.1%, international revenues decreased 8.7%, though they rose 2.6% in constant currency. The company raised its fiscal year 2023 revenue guidance to $1,084 - $1,107 million, expecting a 4.0% - 2.0% decline reported and -1.5% - 0.5% in constant currency. A quarterly dividend of $0.15 per share was announced. The CEO expressed confidence in achieving strategic priorities and sustainable success.
The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has declared a quarterly cash dividend of $0.15 per share. This dividend, which reflects the company’s commitment to returning value to its shareholders, will be payable on March 13, 2023, to stockholders of record as of February 27, 2023. Embecta is a leading pure-play diabetes care company, leveraging nearly a century of experience in insulin delivery to enhance the lives of people with diabetes. The company's passion is evident through its workforce of more than 2,000 employees worldwide, focusing on innovative solutions and partnerships.
Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced its participation in several upcoming investor conferences. Management will hold virtual meetings on February 15, 2023, for the 2023 BTIG Medical Technology Conference. A presentation is scheduled for March 6, 2023, at 2:00 p.m. ET during the 2023 JP Morgan Global High Yield and Leveraged Finance Conference in Miami, FL. Additionally, a virtual session will occur on March 14, 2023, at 8:00 a.m. ET for the 2023 Oppenheimer 33rd Annual Healthcare Conference. Audio webcasts of these events will be available on Embecta’s investor relations website.
Campbell Soup Company (NYSE:CPB) announced the appointment of
Embecta Corp. (Nasdaq: EMBC) recently celebrated the grand opening of its new global headquarters in Parsippany, New Jersey, a significant step for the diabetes care company following its spinoff from Becton, Dickinson and Company in April 2022. The 55,600-square-foot office will house the leadership team, global support functions, and North American commercial operations, supporting approximately 2,000 employees worldwide. CEO Devdatt Kurdikar highlighted the strategic advantages of the location, including access to a skilled workforce and transportation. New Jersey Governor Phil Murphy praised Embecta's commitment to expanding the state's public health infrastructure.
Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced that it will host a conference call on February 14, 2023, at 8:00 a.m. ET to discuss its fiscal Q1 2023 financial results and provide operational updates. Investors can join via a live webcast or teleconference. The call will include a question and answer session, and a replay will be available later that day on the company's investor relations website. As a major player in insulin delivery, Embecta aims to support people with diabetes through innovative solutions, leveraging its nearly century-long legacy.
Embecta Corp. (Nasdaq: EMBC) reported its financial results for the fiscal year ended September 30, 2022. Revenues decreased to $1,129.5 million, down 3.1% year-over-year. The fourth quarter saw revenues of $274.6 million, an 8.7% decline. U.S. and international revenues fell 1.5% and 4.8%, respectively. Gross profit was $774.9 million with a margin of 68.6%. Net income was $223.6 million, a sharp drop from $414.8 million the prior year, influenced by a $58.9 million impairment charge. The company announced a dividend of $0.15 per share and provided preliminary fiscal 2023 guidance of revenues between $1,050 to $1,073 million.
The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has announced a quarterly cash dividend of $0.15 per share, set to be paid on January 11, 2023. This dividend will be distributed to stockholders registered by the close of business on December 30, 2022. Embecta, a leading diabetes care company, leverages nearly a century of experience in insulin delivery to improve the lives of people living with diabetes.
Embecta Corp. (NASDAQ: EMBC) has announced its participation in the upcoming J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 a.m. PT / 12:45 p.m. ET. The company, known for its significant role in diabetes care, previously operated under Becton, Dickinson and Company. Interested parties can access audio webcasts of the presentation through the Company’s investor relations website. With nearly 100 years in insulin delivery, Embecta aims to enhance the lives of individuals with diabetes through innovative solutions and a dedicated workforce of over 2,000 employees worldwide.
Embecta Corp. (EMBC) and Intuity Medical announced a co-promotional agreement to market the POGO Automatic® Blood Glucose Monitoring System across the U.S., effective immediately. Embecta, a leader in diabetes care following its spin-off from BD, aims to enhance diabetes management solutions with this innovative device. POGO Automatic simplifies blood glucose testing using a 10-test cartridge technology, making it the only FDA-cleared automatic blood glucose monitor. This partnership expands Embecta's offerings while supporting Intuity's mission to improve diabetes care.